DURHAM, N.C., Oct. 8, 2021 /PRNewswire/ -- Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, is proud to partner with the National Hemophilia Foundation in ...

FORT LEE, N.J., July 29, 2025 /PRNewswire/ -- Kedrion Biopharma is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Coagulation Factor X ...

DURHAM, N.C., Sept. 28, 2021 /PRNewswire/ -- Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, with US offices in Durham, NC announced today the kick-off of ...

Bio Products Laboratory is partnering up with the National Hemophilia Foundation for a campaign aimed at boosting awareness of an extremely rare bleeding disorder known as hereditary factor X ...

‌Factor VII deficiency is a rare genetic disorder. It occurs when your body can’t produce enough clotting factor VII, which helps in healing wounds. It can be hereditary or be caused by an underlying ...

Factor XIII deficiency is a rare but potentially life‐threatening bleeding disorder that disrupts the final stage of clot stabilisation. As a multifunctional transglutaminase, Factor XIII plays a ...

Factor VII deficiency is a rare, autosomal recessive bleeding disorder marked by reduced levels or dysfunction of coagulation factor VII, a crucial initiator of the extrinsic coagulation cascade.

The MarketWatch News Department was not involved in the creation of this content. FORT LEE, N.J., July 29, 2025 /PRNewswire/ -- Kedrion Biopharma is proud to announce that the U.S. Food and Drug ...